Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)
A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Amylins potential for effective weight loss drugs will propel this stock forward again starting early next year. Look for a doubling within 36 months
Recs
Company continues to have very good results on not only their FDA approved drugs, but their pipeline drugs as well.
Recs
2 great drugs for diabetics... huge market...great pipeline for obesity... will be > $100 by 2009
Recs
This company makes two medications currently on the market for Diabetes. However, one of their effects is the potential for significant weight loss. I believe that Byetta for Type 2 DM will be used within one year to prevent diabetes in at risk individuals and within two to three years as weight loss medication that is both more effective and safer than other medications.
The second drug, Symlin, is sort of an orphan drug for both Type 1 and 2 diabetes. I believe this drug will be available as a weight loss drug within the year. When this happens, Amln will fly through the roof.
Recs
Byetta is the real deal in diabetes treatment. Everything else in this company (and there's some) is gravy to an investor. As all paradigmatic shifts, Byetta will take time but I think it'll be worth the wait.
Recs
One horse show with Byetta. Has had its run up from $16/share to $47/share.
Recs
"Miracle" drugs for diabetics. Sales increasing for the forseeable future. Deep pipeline. Super management.
Recs
20+million diabetics
Recs
Burning cash like it is weeds.
Recs
This company has no where to go but up, albiet slowly. It has a diabetes drug that also helps loose weight. With diabetes and obesity on the rise world wide and Doctors just gaining info on their new drug, it would seem a true winner for all.
Recs
Demand for exenatide is exdeeding capacity (Partnered with Lilly). Collaboration with Alkermes for extended delivery of this product.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 81 - 91 of 91 : « Previous 1 2 3 4 5